# A Study of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, in Children 2 to <18 Years of Age at High Risk of Respiratory Syncytial Virus

> **NCT06097299** · PHASE2 · COMPLETED · sponsor: **ModernaTX, Inc.** · enrollment: 346 (actual)

## Conditions studied

- Respiratory Syncytial Virus

## Interventions

- **BIOLOGICAL:** mRNA-1345
- **BIOLOGICAL:** Placebo

## Key facts

- **NCT ID:** NCT06097299
- **Lead sponsor:** ModernaTX, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-10-24
- **Primary completion:** 2025-06-27
- **Final completion:** 2025-06-27
- **Target enrollment:** 346 (ACTUAL)
- **Last updated:** 2025-07-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06097299

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06097299, "A Study of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, in Children 2 to <18 Years of Age at High Risk of Respiratory Syncytial Virus". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT06097299. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*